Target intelligence / Profile preview

Shiga toxin-producing Escherichia coli (STEC)

Target
STEC
01

Overview

Shiga toxin-producing *Escherichia coli* (STEC) refers to a group of pathogenic *E. coli* bacteria that produce Shiga toxins (Stx1 and/or Stx2), major virulence factors responsible for disease phenotypes such as bloody diarrhea and hemolytic uremic syndrome (HUS)[2][1][3]. STEC are primarily zoonotic, with ruminant animals (especially cattle) as reservoirs. Infection in humans occurs typically via contaminated food or water. Disease severity often correlates with the type and subtype of Shiga toxin produced, with Stx2 and its variants being more commonly associated with severe complications, including HUS and acute renal injury[1][2][5]. The clinically important STEC serotypes include O157:H7 and multiple non-O157 serogroups[5]. Diagnosis rests on the detection of toxin genes or the toxin itself. There are currently no direct therapeutics targeting the bacteria or the toxin, and antibiotic use is generally contraindicated due to increased risk of toxin release and complications[2].

Other names
STECverocytotoxin-producing Escherichia coli (VTEC)enterohemorrhagic Escherichia coli (EHEC; overlaps but not identical to STEC subset)Shiga toxin-positive Escherichia coli
02

Disease associations

Infection
03

Safety considerations

Use of antibiotics can precipitate the release of more Shiga toxin and worsen disease (not a direct property of the "target")risk of hemolytic uremic syndromeacute renal failureneurological complications in infected patients
04

Biomarkers

Presence of *stx1* and *stx2* genes (which encode Shiga toxins)detection of O157 and non-O157 serogroups in stool samples

Beyond the preview

Go deeper on Shiga toxin-producing Escherichia coli (STEC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shiga toxin-producing Escherichia coli (STEC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call